Bioventus (NASDAQ:BVS) Hits New 12-Month High – Still a Buy?

Bioventus Inc. (NASDAQ:BVS)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $12.99 and last traded at $12.9250, with a volume of 57111 shares traded. The stock had previously closed at $12.45.

Analyst Ratings Changes

A number of research firms have issued reports on BVS. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. Finally, Barrington Research reiterated an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $14.75.

Bioventus Trading Up 4.9%

The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 31.85, a PEG ratio of 1.50 and a beta of 0.65. The company has a fifty day moving average price of $10.05 and a 200-day moving average price of $9.33.

Bioventus (NASDAQ:BVS) last posted its earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, research analysts expect that Bioventus Inc. will post 0.79 EPS for the current year.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC increased its holdings in shares of Bioventus by 4.1% during the 4th quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock valued at $44,993,000 after purchasing an additional 236,741 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Bioventus by 4.4% during the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock worth $19,567,000 after buying an additional 122,749 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Bioventus by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after buying an additional 19,388 shares in the last quarter. State Street Corp grew its position in Bioventus by 1.7% during the fourth quarter. State Street Corp now owns 891,024 shares of the company’s stock valued at $6,629,000 after buying an additional 14,590 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Bioventus by 14.1% during the first quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock valued at $7,971,000 after buying an additional 107,930 shares during the period. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.